CompletedPhase 4

Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.

Switzerland57 participantsStarted 2012-01

Plain-language summary

The purpose of this study is to compare two different thromboelastometry (ROTEM) trigger levels for administration of human fibrinogen concentrate (Haemocomplettan P) in the treatment of perioperative dilutional coagulopathy during major pediatric surgery. The study hypothesis is that administration of fibrinogen concentrate triggered by a ROTEM FibTEM MCF \< 13 mm might reduce the total amount of transfused red cell concentrate during 24 hours after start of surgery as compared to a trigger level of ROTEM FibTEM MCF \< 8 mm.

Who can participate

Age range6 Months – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males and Females * Age 6 months to 17 years * Scheduled for elective scoliosis surgery or major craniofacial surgery * Written informed consent has been obtained * Intraoperative hypofibrinogenemia according to definition of treatment groups Exclusion Criteria: * Preexisting congenital or acquired coagulation disorder * Medical history of estimated increased bleeding tendency * Ongoing coagulation therapy * Clinical signs or diagnosis of acute thromboembolism * Intolerance of study drug * Participation at another clinical trial * Pregnant or lactating women

What they're measuring

Total amount of transfused red cell concentrate

Timeframe: 24 hours after start of surgery

Trial details

NCT IDNCT01487837

SponsorUniversity Children's Hospital, Zurich

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-10

View on ClinicalTrials.gov More Blood Coagulation Disorders trials